Targeting interventions specific to the predominant conformation where αvβ3 and CD47 stably coexist in tumors, without directly interfering with CD47 or αvβ3, could potentially mitigate side effects such as hemolysis or the promotion of tumor angiogenesis (see below). This evidence concerns the gene CD47 and neoplasm.